Peregrine Pharmaceuticals, Inc. reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.

Influenza is a viral infection that affects millions of people each year and potentially can cause serious complications, especially in children and older adults.

Researchers from Japan’s RIKEN SNP Research Center, collaborating with a team at the University of California, San Diego (UCSD), have discovered a new genetic variation that affects a child’s risk of getting Kawasaki disease (KD), an illness characterized by acute inflammation of the arteries throughout the body.

Viral infection disrupts the normal response of mammalian cells to outside deleterious forces, cleaving and inactivating a protein called G3BP that helps drive the formation of stress granules, which shelter the messenger RNAs that carry the code for protein formation, said researchers from Baylor College of Medicine in Houston.

Brown University biologists have, for the first time, observed a critical step in membrane fusion, the process that allows for fertilization, viral infection and nerve cell communication. The research, reported in Developmental Cell, sheds new light on this essential biological process.

After a viral infection, a small percentage of the T cells generated to kill virus-infected cells remain on guard to establish long-term immunity. These so-called memory T cells, which derive from a family of immune cells known as CD8 T cells, engage in a self-renewal process that is essential to their persistence. This ongoing process ensures effective protection against any repeat infection by the same virus, even decades later.